96 related articles for article (PubMed ID: 12401904)
1. Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer.
Van Praagh I; Cure H; Leduc B; Charrier S; Le Bouedec G; Achard JL; Ferriere JP; Feillel V; De Latour M; Dauplat J; Chollet P
Oncologist; 2002; 7(5):418-23. PubMed ID: 12401904
[TBL] [Abstract][Full Text] [Related]
2. Vinorelbine, epirubicin, and methotrexate (VEM) as primary treatment in locally advanced breast cancer.
Abrahamova J; Wagnerova M; Kubala E; Malec V; Simova E; Sirakova I; Pavlikova E; Machova D; Kocak I; Pavlikova I; Tuma P; Prausova J; Kroslakova D; Van Praagh I
Oncologist; 2001; 6(4):347-52. PubMed ID: 11524553
[TBL] [Abstract][Full Text] [Related]
3. [A study of the combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer].
Chen CM; Shen KW; Liu GY; Wu J; Lu JS; Zhuang CJ; Han QX; Liu BL; Shao ZM; Shen ZZ
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):745-7. PubMed ID: 16836921
[TBL] [Abstract][Full Text] [Related]
4. Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer.
Nisticò C; De Matteis A; Rossi E; Carnino F; Valenza R; Agostara B; Bria E; Farris A; Cremonesi M; D'Ottavio AM; Vaccaro A; Garufi C; Giunta S; Botti C; Perrone F; Terzoli E
Anticancer Res; 2005; 25(2B):1343-8. PubMed ID: 15865089
[TBL] [Abstract][Full Text] [Related]
5. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Abrial C; Van Praagh I; Delva R; Leduc B; Fleury J; Gamelin E; Sillet-Bach I; Penault-Llorca F; Amat S; Chollet P
Oncologist; 2005 Apr; 10(4):242-9. PubMed ID: 15821244
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
Ma CD; Chen CM; Chen XS; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen ZZ; Shen KW
Anticancer Res; 2008; 28(5B):3093-7. PubMed ID: 19031963
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.
Nisticò C; Garufi C; Barni S; Frontini L; Gallà DA; Giannarelli D; Vaccaro A; D'Ottavio AM; Terzoli E
Ann Oncol; 1999 Aug; 10(8):937-42. PubMed ID: 10509155
[TBL] [Abstract][Full Text] [Related]
9. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study.
Braud AC; Levy E; Feuilhade F; Otmezguine Y; Calitchi E; Kirova Y; Le Bourgeois JP
Am J Clin Oncol; 2002 Jun; 25(3):303-7. PubMed ID: 12040294
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).
Chua S; Smith IE; A'Hern RP; Coombes GA; Hickish TF; Robinson AC; Laing RW; O'Brien ME; Ebbs SR; Hong A; Wardley A; Mughal T; Verrill M; Dubois D; Bliss JM;
Ann Oncol; 2005 Sep; 16(9):1435-41. PubMed ID: 15946977
[TBL] [Abstract][Full Text] [Related]
11. [First-line chemotherapy in operable breast neoplasms: results of 3 protocols].
Cure H; Charrier S; Ferrière JP; Van Praagh I; Assier I; Feillel V; De Latour M; Bay JO; Achard JL; Dauplat J; Chollet P
Bull Cancer; 1997 Jan; 84(1):31-4. PubMed ID: 9180856
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer.
Vici P; Colucci G; Gebbia V; Amodio A; Giotta F; Belli F; Conti F; Gebbia N; Pezzella G; Valerio MR; Brandi M; Pisconti S; Durini E; Giannarelli D; Lopez M
J Clin Oncol; 2002 Jun; 20(11):2689-94. PubMed ID: 12039931
[TBL] [Abstract][Full Text] [Related]
13. Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer.
Vici P; Foggi P; Colucci G; Capomolla E; Brandi M; Giotta F; Gebbia N; Di Lauro L; Valerio MR; Paoletti G; Belli F; Pizza C; Giannarelli D; Lopez M
Anticancer Res; 2005; 25(2B):1309-14. PubMed ID: 15865083
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer--a phase II trial.
Elomaa I; Joensuu H; Blomqvist C
Acta Oncol; 2003; 42(4):309-14. PubMed ID: 12899502
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Boccardo F; Amadori D; Guglielmini P; Sismondi P; Farris A; Agostara B; Gambi A; Catalano G; Faedi M; Rubagotti A
Oncology; 2010; 78(3-4):274-81. PubMed ID: 20530973
[TBL] [Abstract][Full Text] [Related]
16. Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function.
Zekri JM; El-Helw LM; Purohit OP; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):513-6. PubMed ID: 18513930
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological response to primary chemotherapy in operable breast cancer.
Chollet P; Charrier S; Brain E; Curé H; van Praagh I; Feillel V; de Latour M; Dauplat J; Misset JL; Ferrière JP
Eur J Cancer; 1997 May; 33(6):862-6. PubMed ID: 9291806
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Kountourakis P; Missitzis I; Doufexis D; Zobolas V; Pissakas G; Arnogiannaki N; Maliou S; Sotiropoulou A; Ardavanis A
J Cancer Res Clin Oncol; 2011 Feb; 137(2):221-8. PubMed ID: 20387073
[TBL] [Abstract][Full Text] [Related]
19. Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).
Nolè F; Minchella I; Colleoni M; Orvieto E; Munzone E; de Braud F; Peruzzotti G; Martinelli G; Zampino MG; Catania C; Pizzamiglio M; Veronesi P; Zurrida S; Galimberti V; Goldhirsch A; Veronesi U
Ann Oncol; 1999 Aug; 10(8):993-6. PubMed ID: 10509165
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]